 NEW YORK and LONDON, Jan. 04, 2021 GLOBE NEWSWIRE -- Sumitovant Biopharma Ltd., the majority shareholder of Myovant Sciences NYSE: MYOV, announced today that Myovant Sciences, a healthcare company focused on redefining care for women and for men and one of the five healthcare companies in the Sumitovant family of companies, appointed Mr. David Marek as chief executive officer of Myovant Sciences, Inc. Mr. Marek will also serve as principal executive officer of Myovant Sciences Ltd. and as a member of its board of directors. Mr. Marek succeeds Lynn Seely, M.D. 